US-based biopharmaceutical company Galena Biopharma has launched the Abstral (fentanyl) sublingual tablets in the US for the treatment of breakthrough cancer pain. The sublingual (under the tongue) fentanyl tablet has been designed for ...
Tags: Sublingual Tablets, Medicine
Biopharmaceutical company Galena Biopharma has announced patent notification from the European Patent Office for pharmaceutical use of NeuVax (nelipepimut-S) as a vaccine for the prevention of relapse in breast cancer patients. The patent ...
Tags: Galena Biopharma, Neuvax
Galena Biopharma and Leica Biosystems have joined forces to develop a companion diagnostic for Galena's NeuVax(nelipepimut-S or E75),a breast cancer therapeutic. As part of the partnership,Leica's Bond Oracle HER2 IHC System companion ...
Galena Biopharma has reported a net loss of $6.26m, or $0.09 per share, for the third quarter ended 30 September 2012 compared to a net loss of $5.47m, or $0.09 per share, for the third quarter ended 30 September 2011. Operating loss for ...
Tags: Net Loss, operational and business development, patient enrollment
The US Patent and Trademark Office (USPTO) has issued a key patent covering the use of Galena Biopharma's NeuVax for inducing immunity to breast cancer recurrence in patients having low-to-intermediate IHC levels of 1+ or 2+ and a FISH ...